<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>IDE</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>MMI gets IDE for robotic microsurgical study in Alzheimer’s</title>
      <author>holland.johnson@clarivate.com</author>
      <description>
        <![CDATA[Medical Microinstruments Inc., reported the U.S. FDA approval of an investigational device exemption for a study using its Symani surgical system for treating Alzheimer’s disease, one of its earliest forays into the brain.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725948</guid>
      <pubDate>Mon, 10 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725948-mmi-gets-ide-for-robotic-microsurgical-study-in-alzheimers</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/Symani-system-28feb24.webp?t=1709161095" type="image/jpeg" medium="image" fileSize="66270">
        <media:title type="plain">Symani system</media:title>
        <media:description type="plain">The Symani surgical system allows surgeons to replicate hand movements at a micro level. Credit: Symani</media:description>
      </media:content>
    </item>
    <item>
      <title>CG Bio, Nexgel developing long-acting drug delivery system</title>
      <description>
        <![CDATA[Nexgel Biotech Co. Ltd. and CG Bio Co. Ltd. agreed to co-develop a thermosensitive polyphosphazene hydrogel-based long-acting drug delivery platform through a new collaboration agreement signed Oct. 31.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725510</guid>
      <pubDate>Tue, 04 Nov 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725510-cg-bio-nexgel-developing-long-acting-drug-delivery-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Collaboration-illustration.webp?t=1600375790" type="image/png" medium="image" fileSize="669559">
        <media:title type="plain">Deal illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Onward Medical receives FDA IDE for BP study with ARC-IM system</title>
      <description>
        <![CDATA[Onward Medical NV secured U.S. FDA investigational device exemption (IDE) approval for a pivotal study to assess the safety and efficacy of its implantable spinal stimulation technology, the ARC-IM system. The Empower study BP study will focus on addressing blood pressure instability in patients with spinal cord injury (SCI). ]]>
      </description>
      <guid>http://www.bioworld.com/articles/723176</guid>
      <pubDate>Tue, 19 Aug 2025 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723176-onward-medical-receives-fda-ide-for-bp-study-with-arc-im-system</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2025/Onward-Arc-IM-system-5mar25.webp?t=1741215897" type="image/jpeg" medium="image" fileSize="197021">
        <media:title type="plain">Onward Arc IM system</media:title>
        <media:description type="plain">Onward Arc IM system. Credit: Onward Medical</media:description>
      </media:content>
    </item>
    <item>
      <title>Newronika gets IDE from the FDA for adaptive DBS trial</title>
      <description>
        <![CDATA[Newronika SpA's AlphaDBS recently secured an investigational device exemption from the U.S. FDA allowing it to begin a pivotal trial to evaluate the safety and efficacy of its adaptive deep brain stimulation system in patients with movement disorders, including Parkinson's disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/716907</guid>
      <pubDate>Tue, 11 Feb 2025 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/716907-newronika-gets-ide-from-the-fda-for-adaptive-dbs-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2023/DBS-for-stroke-6-25.webp?t=1692996708" type="image/jpeg" medium="image" fileSize="94182">
        <media:title type="plain">DBS for stroke </media:title>
        <media:description type="plain">In the EDEN trial, a single DBS lead was implanted into the cerebellum and connected to a pacemaker-like device in the upper back. Credit: Courtesy of Cleveland Clinic</media:description>
      </media:content>
    </item>
    <item>
      <title>Deepqure gets FDA IDE nod for renal denervation device trial</title>
      <description>
        <![CDATA[As renal denervation (RDN) makes a comeback for treatment-resistant hypertension, Deepqure Inc. is advancing its RDN medical device dubbed Hyperqure with the U.S. FDA granting clearance for a U.S.-based study.]]>
      </description>
      <guid>http://www.bioworld.com/articles/709248</guid>
      <pubDate>Tue, 11 Jun 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/709248-deepqure-gets-fda-ide-nod-for-renal-denervation-device-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2024/DeepQure-11june24.webp?t=1718139682" type="image/jpeg" medium="image" fileSize="132378">
        <media:title type="plain">DeepQure</media:title>
        <media:description type="plain">Deepqure. Credit: Deepqure</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA advances AI-enhanced tech for prostate diagnosis and treatment</title>
      <description>
        <![CDATA[Recent U.S. FDA actions could transform decades of prostate cancer care. Two companies focused on prostate cancer received good news from the FDA for their artificial intelligence (AI)-driven software. Bot Image Inc. gained FDA clearance for its medical device computer-aided detection and diagnostic tool, Prostatid. The agency also provided FDA investigational device exemption for Avenda Health Inc.’s Focalpoint ablation system that enables more accurate mapping of a patient’s prostate cancer for better surgical results.]]>
      </description>
      <guid>http://www.bioworld.com/articles/521460</guid>
      <pubDate>Tue, 09 Aug 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/521460-fda-advances-ai-enhanced-tech-for-prostate-diagnosis-and-treatment</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/Man-MRI-prostate.webp?t=1660081706" type="image/png" medium="image" fileSize="1365665">
        <media:title type="plain">Man undergoing MRI scan for prostate cancer diagnosis</media:title>
      </media:content>
    </item>
    <item>
      <title>Cardialen wins FDA IDE approval for low-energy pulse therapy </title>
      <description>
        <![CDATA[The FDA granted Cardialen Inc. an investigational device exemption (IDE) to begin a clinical trial of its Multipulse Therapy (MPT) to treat paroxysmal and persistent atrial fibrillation (AF). MPT is a low-energy electrical pulse therapy aimed at restoring abnormally rapid heart rates, such as AF, to a regular rhythm to reduce the potential for high-energy shocks. Studies have shown that almost 1 in 4 patients experience anxiety or depression after receiving an implantable cardioverter defibrillator (ICD).]]>
      </description>
      <guid>http://www.bioworld.com/articles/513522</guid>
      <pubDate>Thu, 18 Nov 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/513522-cardialen-wins-fda-ide-approval-for-low-energy-pulse-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Cardiovascular.webp?t=1767812610" type="image/png" medium="image" fileSize="412733">
        <media:title type="plain">Cardiovascular illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>FDA draft for investigator safety reporting offers little detail on combo product studies</title>
      <description>
        <![CDATA[The FDA unveiled a draft guidance addressing the responsibilities of clinical investigators for safety reporting for investigational drugs and devices, a novel attempt to combine the disparate adverse event reporting timelines for investigational drugs and devices.]]>
      </description>
      <guid>http://www.bioworld.com/articles/511905</guid>
      <pubDate>Wed, 29 Sep 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/511905-fda-draft-for-investigator-safety-reporting-offers-little-detail-on-combo-product-studies</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FDA-yellow-dice.webp?t=1626471222" type="image/png" medium="image" fileSize="416581">
        <media:title type="plain">Hand holding FDA blocks</media:title>
      </media:content>
    </item>
    <item>
      <title>Livanova gets FDA nod for pivotal sleep apnea trial</title>
      <description>
        <![CDATA[Livanova plc has launched an IDE trial of its Aura6000 sleep apnea device, following approval by the FDA to proceed with the study. The implantable pulse generator (IPG) is designed to treat patients with moderate to severe obstructive sleep apnea (OSA) who do not get relief from a traditional continuous positive airway pressure (CPAP) machine or refuse to use one.]]>
      </description>
      <guid>http://www.bioworld.com/articles/508313</guid>
      <pubDate>Thu, 17 Jun 2021 11:01:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/508313-livanova-gets-fda-nod-for-pivotal-sleep-apnea-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/06-16-Livanova-Aura6000.webp?t=1623876935" type="image/png" medium="image" fileSize="285207">
        <media:title type="plain">Aura6000 device, illustration showing placement</media:title>
        <media:description type="plain">Aura6000 sleep apnea device. Credit: Livanova plc</media:description>
      </media:content>
    </item>
    <item>
      <title>Acutus rings up regulatory approvals</title>
      <description>
        <![CDATA[Acutus Medical Inc. scored big with regulators in recent weeks. The company, which focuses on devices to diagnose and treat cardiac arrhythmias, received FDA approval to launch an investigational device exemption clinical trial for its Acqblate Force sensing ablation catheter and system in atrial fibrillation just two weeks after gaining CE mark approval for a broad suite of electrophysiology products.]]>
      </description>
      <guid>http://www.bioworld.com/articles/508259</guid>
      <pubDate>Tue, 15 Jun 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/508259-acutus-rings-up-regulatory-approvals</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/06-15-Acutus-Acqmap-console.webp?t=1623793586" type="image/png" medium="image" fileSize="1403131">
        <media:title type="plain">Acqmap console image</media:title>
        <media:description type="plain">Acqmap imaging and mapping system. Credit: Acutus Medical Inc. </media:description>
      </media:content>
    </item>
    <item>
      <title>Neurescue’s aortic occlusion device gets FDA nod for hemorrhage and IDE for cardiac arrest</title>
      <description>
        <![CDATA[The FDA granted Neurescue a &quot;two-fer&quot; on its intelligent balloon catheter for aortic occlusion with 510(k) clearance for emergency control of hemorrhage and investigational device exemption for use in cardiac arrest. By inflating a soft balloon at diaphragm level, the device dramatically increases perfusion to the heart, brain and lungs within a minute of deployment via the femoral artery.]]>
      </description>
      <guid>http://www.bioworld.com/articles/508088</guid>
      <pubDate>Thu, 10 Jun 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/508088-neurescues-aortic-occlusion-device-gets-fda-nod-for-hemorrhage-and-ide-for-cardiac-arrest</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/06-10-NEURESCUE-Device.webp?t=1623361332" type="image/png" medium="image" fileSize="689759">
        <media:title type="plain">Neurescue device image</media:title>
        <media:description type="plain">Intelligent balloon catheter for aortic occlusion. Credit: Neurescue</media:description>
      </media:content>
    </item>
    <item>
      <title>Atheart Medical begins IDE trial for septal closure device</title>
      <description>
        <![CDATA[Atheart Medical Inc. came on the market with splash, simultaneously announcing the company&rsquo;s formation and its launch of a U.S. investigational device exemption (IDE) trial for the Resept ASD occluder, a device designed to close atrial septal defects. Resept features a metal-free, bioresorbable frame to reduce the risks associated with the long-term presence of metal in the heart.]]>
      </description>
      <guid>http://www.bioworld.com/articles/506261</guid>
      <pubDate>Thu, 22 Apr 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/506261-atheart-medical-begins-ide-trial-for-septal-closure-device</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/04-22-Atheart-Resept-ASD-Occluder.webp?t=1619127189" type="image/png" medium="image" fileSize="416607">
        <media:title type="plain">Resept ASD occluder image</media:title>
        <media:description type="plain">Resept ASD occluder. Credit: Atheart Medical Inc. </media:description>
      </media:content>
    </item>
    <item>
      <title>FDA OKs IDE trial of Agnovos Healthcare’s breakthrough spine device</title>
      <description>
        <![CDATA[Agnovos Healthcare LLC, a company using regenerative medicine to treat localized effects of bone disease, has received the FDA&rsquo;s nod for an IDE clinical trial to assess its AGN1 local osteo-enhancement procedure (LOEP) small-volume (SV) kit in patients with vertebral compression fractures (VCFs). The investigational device is intended to treat stable but painful VCFs via a minimally invasive procedure. The kit, which comes in the form of two single-use trays, contains a calcium-based, resorbable, triphasic implant material that is designed to align the pace of resorption with bone formation, providing treated vertebrae with immediate and durable protection.]]>
      </description>
      <guid>http://www.bioworld.com/articles/506090</guid>
      <pubDate>Mon, 19 Apr 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/506090-fda-oks-ide-trial-of-agnovos-healthcares-breakthrough-spine-device</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/04-19-Agnovos-AGN1-kit.webp?t=1618868914" type="image/png" medium="image" fileSize="931126">
        <media:title type="plain">AGN1 LEOP SV kit image</media:title>
        <media:description type="plain">The AGN1 LEOP SV kit, which comes in the form of two single-use trays, contains a calcium-based, resorbable, triphasic implant material that is designed to align the pace of resorption with bone formation. Credit: Agnovos Healthcare LLC</media:description>
      </media:content>
    </item>
    <item>
      <title>Hancock Jaffe prepares for Venovalve pivotal trial</title>
      <description>
        <![CDATA[The FDA granted an investigational device exemption (IDE) to Hancock Jaffe Laboratories Inc. for Venovalve, clearing the way for the company to begin a pivotal trial of the implantable valve in patients with chronic venous insufficiency (CVI) of the deep veins of the leg. The company&rsquo;s first patent covering the device was issued by the U.S. Patent and Trademark Office on April 7.]]>
      </description>
      <guid>http://www.bioworld.com/articles/505935</guid>
      <pubDate>Wed, 14 Apr 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/505935-hancock-jaffe-prepares-for-venovalve-pivotal-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/04-14-Hancock-Jaffe-Venovalve.webp?t=1618436535" type="image/png" medium="image" fileSize="402230">
        <media:title type="plain">Venovalve product rendering</media:title>
        <media:description type="plain">Venovalve. Credit: Hancock Jaffe Laboratories Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA gives nod to Virtual Incision to start study of MIRA Platform</title>
      <description>
        <![CDATA[Virtual Incision Corp. revealed that it had received a green light from the U.S. FDA to begin its study of its miniaturized in vivo robotic assistant (MIRA) Platform. Initially, the company will focus the platform on minimally invasive laparoscopic colon surgery. With the MIRA Platform, the company will aim to enter a growing market in the U.S., where more than 400,000 colon resection procedures are performed each year.]]>
      </description>
      <guid>http://www.bioworld.com/articles/499483</guid>
      <pubDate>Tue, 27 Oct 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/499483-fda-gives-nod-to-virtual-incision-to-start-study-of-mira-platform</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/10-27-Virtual-Incision-MIRA.webp?t=1603835477" type="image/png" medium="image" fileSize="368490">
        <media:title type="plain">Product image</media:title>
        <media:description type="plain">Miniaturized in vivo robotic assistant (MIRA) Platform. Credit: Virtual Incision Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Positive results seen with Shockwave IVL in pivotal IDE study</title>
      <description>
        <![CDATA[Shockwave Medical Inc., which is focused on intravascular lithotripsy (IVL) to treat severely calcified cardiovascular disease, saw its stock value rise Friday (NASDAQ:SWAV), eventually closing at $78.22, up $3.47, or 4.64%, following the presentation of positive results from the Disrupt CAD III trial.]]>
      </description>
      <guid>http://www.bioworld.com/articles/499077</guid>
      <pubDate>Fri, 16 Oct 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/499077-positive-results-seen-with-shockwave-ivl-in-pivotal-ide-study</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/cardiovascular-plaque-coronary-calcification-heart-attack.webp?t=1602885334" type="image/png" medium="image" fileSize="153184">
        <media:title type="plain">Illustration of calcified artery, heart</media:title>
      </media:content>
    </item>
    <item>
      <title>Carag secures IDE approval for Bioresorbable Septal Occluder</title>
      <description>
        <![CDATA[Carag AG received investigational device exemption (IDE) approval from the U.S. FDA for its Carag Bioresorbable Septal Occluder (CBSO). The device is the first transcatheter septal occluder with a nonmetal, bioresorbable framework. The Baar, Switzerland-based company plans a &quot;swift start&quot; for a staged study trial in the U.S. with 250 patients, Carag&#39;s CEO J&eacute;r&ocirc;me Bernhard told <em>BioWorld</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/436241</guid>
      <pubDate>Thu, 02 Jul 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/436241-carag-secures-ide-approval-for-bioresorbable-septal-occluder</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/7-2-Carag-Bioresorbable-Septal-Occluder.webp?t=1593724857" type="image/png" medium="image" fileSize="668027">
        <media:title type="plain">Product image</media:title>
        <media:description type="plain">Carag Bioresorbable Septal Occluder. Credit: Carag AG</media:description>
      </media:content>
    </item>
    <item>
      <title>Ancora Heart gets FDA nod for Accucinch pivotal trial</title>
      <description>
        <![CDATA[The U.S. FDA has greenlighted Ancora Heart Inc.&rsquo;s IDE request to conduct the Corcinch-HF pivotal clinical trial. The study is intended to demonstrate the safety and effectiveness of the Accucinch ventricular restoration system in patients with heart failure and reduced ejection fraction (HFrEF).]]>
      </description>
      <guid>http://www.bioworld.com/articles/436161</guid>
      <pubDate>Tue, 30 Jun 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/436161-ancora-heart-gets-fda-nod-for-accucinch-pivotal-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/6-30-Ancora-Heart-Accucinch.webp?t=1593552889" type="image/png" medium="image" fileSize="776391">
        <media:title type="plain">Accucinch in heart model</media:title>
        <media:description type="plain">Accucinch ventricular restoration system. 
Credit: Ancora Heart Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA greenlights Balt’s STEM trial for subdural hematoma</title>
      <description>
        <![CDATA[Balt USA LLC, of Irvine, Calif., has received a thumbs up from the FDA to begin an IDE trial of its Squid liquid embolic device for the treatment of chronic subdural hematoma (cSDH). The nonadhesive agent offers a minimally invasive option for a disabling neurological condition that often requires brain surgery to correct.]]>
      </description>
      <guid>http://www.bioworld.com/articles/435184</guid>
      <pubDate>Mon, 18 May 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/435184-fda-greenlights-balts-stem-trial-for-subdural-hematoma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/neurology-subdural-hematoma-brain-scan.webp?t=1729025504" type="image/jpeg" medium="image" fileSize="156412">
        <media:title type="plain">CT scan of brain showing subdural hematoma</media:title>
        <media:description type="plain">CT scan of brain showing subdural hematoma.</media:description>
      </media:content>
    </item>
    <item>
      <title>Setpoint Medical's platform receives IDE approval</title>
      <description>
        <![CDATA[The FDA granted Setpoint Medical Corp. an investigational device exemption (IDE) approval to study its bioelectronic platform in rheumatoid arthritis (RA) patients. The Valencia, Calif.-based company expects to begin enrollment in a multicenter, double-blind, randomized, sham-controlled pivotal trial in patients with RA in the third quarter of 2020, Setpoint President and CEO Murthy Simhambhatla told <em>BioWorld</em>.]]>
      </description>
      <guid>http://www.bioworld.com/articles/435018</guid>
      <pubDate>Mon, 11 May 2020 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/435018-setpoint-medicals-platform-receives-ide-approval</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/neuron-network.webp?t=1589299508" type="image/png" medium="image" fileSize="484029">
        <media:title type="plain">Neural network</media:title>
      </media:content>
    </item>
    <item>
      <title>Beyond Air seeks IDE for nitric oxide treatment for COVID-19</title>
      <description>
        <![CDATA[As companies scramble to develop diagnostic tests and vaccines for COVID-19, there is a need for effective treatments for patients suffering severe respiratory effects from the novel coronavirus. To that end, Beyond Air Inc., of Garden City, N.Y., and Rehovot, Israel, has applied to the U.S. FDA to conduct an IDE trial of its inhaled nitric oxide (NO) system, Lungfit Bro, in COVID-19 patients.]]>
      </description>
      <guid>http://www.bioworld.com/articles/433778</guid>
      <pubDate>Tue, 17 Mar 2020 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/433778-beyond-air-seeks-ide-for-nitric-oxide-treatment-for-covid-19</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/3-17-Beyond-Air-Lung-BRO.webp?t=1584480239" type="image/png" medium="image" fileSize="198321">
        <media:title type="plain">3-17-Beyond-Air-Lung-BRO.png</media:title>
        <media:description type="plain">Lungfit Bro. Credit: Beyond Air Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Alydia Health wraps up enrollment in pivotal study of device postpartum hemorrhage</title>
      <description>
        <![CDATA[Alydia Health Inc., of Menlo Park, Calif., has completed enrollment in the pivotal PEARLE investigational device exemption (IDE) study, which is assessing the safety and effectiveness of the Jada system to rapidly control and treat abnormal postpartum uterine bleeding and postpartum hemorrhage. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/433090</guid>
      <pubDate>Fri, 14 Feb 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/433090-alydia-health-wraps-up-enrollment-in-pivotal-study-of-device-postpartum-hemorrhage</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Pediatric/labor-delivery-birth-obgyn.webp?t=1745266620" type="image/jpeg" medium="image" fileSize="182277">
        <media:title type="plain">Woman giving birth</media:title>
      </media:content>
    </item>
    <item>
      <title>GI Dynamics enrolls first patient in pivotal Endobarrier trial</title>
      <description>
        <![CDATA[GI Dynamics Inc.&rsquo;s U.S. IDE trial of Endobarrier, which is designed for patients diagnosed with type 2 diabetes and obesity, is now underway with the first patient enrollment at Michigan Medicine in Ann Arbor, Mich. The FDA approved the pivotal STEP-1 clinical trial in August 2019 to evaluate the Endobarrier as a barrier between the small intestine and food to reduce calorie intake.]]>
      </description>
      <guid>http://www.bioworld.com/articles/432688</guid>
      <pubDate>Tue, 28 Jan 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/432688-gi-dynamics-enrolls-first-patient-in-pivotal-endobarrier-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2020/1-28-GI-dynamics-endobarier-hero.webp?t=1580252946" type="image/png" medium="image" fileSize="1121535">
        <media:title type="plain">1-28-GI-dynamics-endobarrier-hero.png</media:title>
        <media:description type="plain">Illustration of Endobarrier placement. Credit: GI Dynamics Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>FDA greenlights Ra Medical’s DABRA atherectomy trial</title>
      <description>
        <![CDATA[Ra Medical Systems Inc., of Carlsbad, Calif., reported that the U.S. FDA has granted investigational device exemption (IDE) approval to study its DABRA excimer laser system as an atherectomy device to treat peripheral vascular stenosis. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/432567</guid>
      <pubDate>Wed, 22 Jan 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/432567-fda-greenlights-ra-medicals-dabra-atherectomy-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/regulatory-green-light-approved.webp?t=1588870615" type="image/png" medium="image" fileSize="516919">
        <media:title type="plain">Green traffic light</media:title>
      </media:content>
    </item>
    <item>
      <title>PGDx receives IDE approval to support Merck’s precision oncology trial</title>
      <description>
        <![CDATA[The U.S. FDA has granted investigational device exemption approval for the use of Personal Genome Diagnostics Inc.&rsquo;s (PGDx) elio tissue complete assay in a Merck &amp; Co. Inc. trial of a Keytruda (pembrolizumab)-based combination therapy. Specifically, the assay will be used during the trial to analyze genomic markers to direct patient enrollment and stratification.]]>
      </description>
      <guid>http://www.bioworld.com/articles/431553</guid>
      <pubDate>Wed, 04 Dec 2019 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/431553-pgdx-receives-ide-approval-to-support-mercks-precision-oncology-trial</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2019/PGDx-elio12-4.webp?t=1575497078" type="image/png" medium="image" fileSize="1157959">
        <media:title type="plain">PGDx-elio12-4.png</media:title>
      </media:content>
    </item>
    <item>
      <title>Pq Bypass gets FDA OK to launch Torus SFA stent graft pivotal trial</title>
      <description>
        <![CDATA[The U.S. FDA has given Pq Bypass Inc. the greenlight to conduct a pivotal trial aimed at assessing its Torus stent graft in the treatment of peripheral artery disease (PAD) in the superficial femoral artery. The TORUS-2 study is the Milpitas, Calif.-based startup's second IDE approval in less than two years and the first pivotal IDE for an SFA stent graft since W.L. Gore & Associates Inc.'s Viabahn device, which notched an initial PMA approval in 2005.]]>
      </description>
      <guid>http://www.bioworld.com/articles/430102</guid>
      <pubDate>Wed, 09 Oct 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/430102-pq-bypass-gets-fda-ok-to-launch-torus-sfa-stent-graft-pivotal-trial</link>
    </item>
    <item>
      <title>FDA grants IDE approval for pivotal study of Avita Medical's Recell system</title>
      <description>
        <![CDATA[Melbourne, Australia-based regenerative medicine company Avita Medical Ltd. has received good news from the FDA. The company, which also has a presence in Valencia, Calif., said the agency gave its thumbs up to an investigational device exemption application for a pivotal trial (NCT04091672) evaluating the safety and effectiveness of the Recell autologous cell harvesting device in combination with meshed autografting for the treatment of acute full-thickness skin defects, such as degloving, crush wounds, abrasions, lacerations and surgical wounds.]]>
      </description>
      <guid>http://www.bioworld.com/articles/430199</guid>
      <pubDate>Wed, 18 Sep 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/430199-fda-grants-ide-approval-for-pivotal-study-of-avita-medicals-recell-system</link>
    </item>
  </channel>
</rss>
